Two pharmaceutical giants—Eli Lilly and Novo Nordisk—dominate the glucagon-like peptide-1 market, giving them substantial leverage in pricing negotiations. The Trump administration’s voluntary agreement with these manufacturers permits them to maintain high list prices while subsidizing patient costs through assistance programs, effectively preserving profit margins while creating superficial affordability.
Data analysis reveals that while list price maintenance remains at 85 percent and patient assistance programs cover 72 percent of cases, actual out-of-pocket cost reduction reaches only 38 percent. This disconnect illustrates how structural design flaws enable manufacturers to shift financial burden without reducing underlying medication expenses.
Market concentration among two major players, combined with voluntary agreement limitations, reduces competitive pressure for genuine price reduction and sustainable affordability improvements.
Read the full article on GMJ Newsroom.
Was this article helpful?
